PMGC Holdings subsidiary NorthStrive Biosciences reports Phase III AI drug-discovery hits, four compounds raise ANT1 up to 50%
PMGC Holdings reported that NorthStrive Biosciences' Phase III AI-driven program validated four small-molecule candidates that increase ANT1 expression in human skeletal muscle cells.Key Highlights:Original SEC Filing: PMGC Holdings Inc. [ ELAB ] - 8-K - Jul. 01, 2026This is an AI-powered summary…